Vectura Group plc Vectura host Capital Markets Event today in London
June 28 2017 - 1:01AM
RNS Non-Regulatory
TIDMVEC
Vectura Group plc
28 June 2017
Vectura Group plc
Vectura hosts Capital Markets Event today in London
Chippenham, UK - 28 June 2017: Vectura Group plc (LSE: VEC)
("the Group"), an industry-leading inhaled airways disease focused
business, is holding a Capital Markets Event for analysts and
institutional investors today in London, starting at 13:00 BST.
James Ward-Lilley, Chief Executive Officer, will host the event
together with members of the Executive Leadership and senior
management teams. In addition, Tim Harrison, Professor of Asthma
and Respiratory Medicine at The Asthma Centre, Nottingham
Respiratory Research Unit, and lead investigator for Vectura's
wholly owned pipeline candidate, VR475, will provide a clinical
perspective on the Asthma and COPD landscape.
A live webcast of the event, with the presentation slides, will
be available on Vectura's website at:
http://www.vectura.com/investors/presentations-webcasts/ No new
price sensitive information will be disclosed.
- ENDS -
For more enquiries, please contact
Vectura Group plc +44 (0)1249 667700
Andrew Derodra - Chief Financial Officer
Fleur Wood - Director Communications
Elizabeth Knowles - Director Investor Relations and Analysis
Consilium Strategic Communications +44 (0)20 3709 5700
Mary-Jane Elliott / Sue Stuart / Jessica Hodgson vectura@consilium-comms.com
About Vectura
Vectura, a FTSE250 company listed on the London Stock Exchange
(LSE: VEC), is an industry-leading inhaled airways disease focused
business with proprietary formulation and devices across DPI, pMDI
and "smart" nebulisation platforms. With our extensive range of
technologies, capabilities and collaborations, we believe we can
become a leader in the development of inhalation products,
increasing our ability to help patients suffering from respiratory
diseases. In June 2016 Vectura completed a merger with Skyepharma
PLC.
Vectura has seven inhaled, four non-inhaled and ten oral
products marketed by partners with growing global royalty streams,
and a portfolio of drugs in clinical development, a number of which
have licence agreements with several global pharmaceutical and
biotechnology companies including Hikma, Novartis, Sandoz,
Mundipharma, Kyorin, Baxter, GSK, UCB, Ablynx, Grifols, Chiesi,
Almirall, Janssen, and Tianjin KingYork.
For further information, please visit Vectura's website at
www.vectura.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRADMGZVVNLGNZM
(END) Dow Jones Newswires
June 28, 2017 02:01 ET (06:01 GMT)
Vectura (LSE:VEC)
Historical Stock Chart
From Apr 2024 to May 2024
Vectura (LSE:VEC)
Historical Stock Chart
From May 2023 to May 2024